In addition, the low treatment efficacy of anti EGFR monoclonal antibodies in patients with CRC was reported, and these outcomes highlighted the necessity of investigation on the potential predictive markers for response to cetuximab [19, 39, 40]. The gene discussed is EGFR; the disease is colorectal carcinoma.